Other and unspecified immunodeficiencies with predominantly antibody defects

DOID MESH Endpoint Browser PheWeb

D3_IMMUDEFANTIBODYNAS

No definition available.

Endpoint definition

↥

FinnGen phenotype data

429209 individuals

Apply sex-specific rule None

429209

Check conditions None

429209

Check pre-conditions, main-only, mode, registry filters

Hospital Discharge: ICD-10 D80.8, D80.9

Hospital discharge: ICD-9 2790C|2790X

Cause of death: ICD-10 D80.8, D80.9

Cause of death: ICD-9 2790C|2790X

2 out of 7 registries used, show all original rules.

369

Check minimum number of events None

369

Include endpoints None

369

Remove individuals based on genotype QC

357

D3_IMMUDEFANTIBODYNAS

Control definitions

Control exclude D3_IMMUNEMECHANISM

Extra metadata

Level in the ICD hierarchy 4

First used in FinnGen datafreeze DF2

NAME	D3_IMMUDEFANTIBODYNAS
CONTROL_EXCLUDE	D3_IMMUNEMECHANISM
CONTROL_PRECONDITIONS
CONTROL_CONDITIONS
SEX
INCLUDE
PRE_CONDITIONS
CONDITIONS
OUTPAT_ICD
OUTPAT_OPER
HD_MAINONLY
HD_ICD_10_ATC
HD_ICD_10	D80[8-9]
HD_ICD_9	2790C\|2790X
HD_ICD_8	$!$	The FinnGen clinical team has checked and no code can be used for this rule.
HD_ICD_10_EXCL
HD_ICD_9_EXCL
HD_ICD_8_EXCL
COD_MAINONLY
COD_ICD_10	D80[8-9]
COD_ICD_9	2790C\|2790X
COD_ICD_8	$!$	The FinnGen clinical team has checked and no code can be used for this rule.
COD_ICD_10_EXCL
COD_ICD_9_EXCL
COD_ICD_8_EXCL
OPER_NOM
OPER_HL
OPER_HP1
OPER_HP2
KELA_REIMB
KELA_REIMB_ICD
KELA_ATC_NEEDOTHER
KELA_ATC
KELA_VNRO_NEEDOTHER
KELA_VNRO
CANC_TOPO
CANC_TOPO_EXCL
CANC_MORPH
CANC_MORPH_EXCL
CANC_BEHAV

Show upset plot detailing case counts by codes

Or the full data table

Similar endpoints

↥

List of similar endpoints to Other and unspecified immunodeficiencies with predominantly antibody defects based on the number of shared cases.

Broader endpoints:

Narrower endpoints:

None

Show all endpoint correlations

Summary Statistics

↥

Key figures

	All	Female	Male
Number of individuals	357	236	121
Unadjusted prevalence (%)	0.09	0.10	0.07
Mean age at first event (years)	47.11	47.61	46.13

Mortality

Follow-up	Absolute risk	HR [95% CI]	p	N
1998–2019	0.39	23.67 [8.88, 63.13]	2.6e-10	33
15 years	0.05	7.18 [2.51, 20.50]	2.3e-4	10
5 years	0.03	19.48 [6.98, 54.39]	1.4e-8	11
1 year	0.03	113.57 [44.88, 287.37]	1.7e-23	12

Age distribution of first events

Year distribution of first events

Cumulative Incidence

Correlations

↥

Index endpoint: D3_IMMUDEFANTIBODYNAS – Other and unspecified immunodeficiencies with predominantly antibody defects
GWS hits:

Survival analyses between endpoints

↥

Plot

before Other and unspecified immunodeficiencies with predominantly antibody defects
after Other and unspecified immunodeficiencies with predominantly antibody defects

Loading survival analyses plot

Table

Loading survival analyses table

Drugs most likely to be purchased after Other and unspecified immunodeficiencies with predominantly antibody defects

↥

Endpoint not on priority list, no data to show.

≡ Risteys

R10

R9

R8

R7

R6

R5

R4

R3